secukinumab - Robuta Search

https://pubmed.ncbi.nlm.nih.gov/38685124/ Effectiveness of secukinumab in patients with psoriasis and psoriatic arthritis in a Saudi... In a Saudi real-world setting, secukinumab proved to be an efficient medication with high efficacy and retention rates. in patients https://open.library.emory.edu/concern/publications/d0885063-79da-413e-8c6f-574adac6cd87?locale=en Secukinumab Therapy in Refractory Juvenile Idiopathic Arthritis | OpenEmory Secukinumab Therapy in Refractory Juvenile Idiopathic Arthritis juvenile idiopathic arthritis secukinumab therapy refractory https://www.nice.org.uk/guidance/TA445/history History | Certolizumab pegol and secukinumab for treating active psoriatic arthritis after... Evidence-based recommendations on certolizumab pegol (Cimzia) and secukinumab (Cosentyx) for treating active psoriatic arthritis in adults active psoriatic arthritis certolizumab pegol history secukinumab https://dukespace.lib.duke.edu/items/5f3d3e01-83f9-462b-bc1a-55a0b0641635/full Pyoderma gangrenosum induced by secukinumab in a patient with psoriasis successfully treated with... pyoderma gangrenosum https://adisinsight.springer.com/drugsafety/803926312?error=cookies_not_supported&code=54d16fa0-5804-43c0-a8ba-8764a9ce92b2 Secukinumab - AdisInsight Four patients with active systemic lupus erythematosus (SLE) [ages and sexes not stated] received secukinumab for active cutaneous disease, inflammatory secukinumab adisinsight https://adisinsight.springer.com/trials/700303188?error=cookies_not_supported&code=e044dbf9-a4a7-446e-ba60-57e9a2684a40 An Open-label Proof of Concept Study Regarding the Use of Secukinumab (Cosentyx) in Patients With... This study investigates the efficacy of secukinumab in necrobiosis lipoidica diabeticorum (NLD). https://adisinsight.springer.com/drugsafety/803923666?error=cookies_not_supported&code=e98eb692-6295-41a6-97dc-26f75cf132eb Secukinumab - AdisInsight A report described 54 patients with recurrent spontaneous abortion and T helper 17/T regulatory cell imbalance who received subcutaneous secukinumab 3 mg/kg in secukinumab adisinsight https://adisinsight.springer.com/trials/700317916?error=cookies_not_supported&code=9798cd73-b657-4b43-82f7-00c636f1ed88 Outcomes With Treatment and Withdraw of Secukinumab in Patients With Plaque Psoriasis Compared to... Psoriasis (PsO) is a systemic immune disease that affect 2-4% of the population worldwide. PsO causes tremendous burden in terms of quality of life, https://adisinsight.springer.com/drugsafety/803400918?error=cookies_not_supported&code=ddb1760d-9032-49b9-a615-b7613939a732 Secukinumab - AdisInsight A 36-year-old woman developed eruptive lentiginosis during treatment with secukinumab for psoriasis and psoriatic arthritis.The woman, who had Fitzpatrick skin secukinumab adisinsight https://adisinsight.springer.com/drugsafety/803455720?error=cookies_not_supported&code=414d6db4-b426-4101-b2eb-c8c91511f74e Secukinumab - AdisInsight A 54-year-old woman developed paradoxical psoriasis during treatment with secukinumab for ankylosing spondylitis (AS).The woman, who had a medical history of secukinumab adisinsight https://adisinsight.springer.com/drugsafety/803906694?error=cookies_not_supported&code=6821d2d5-11eb-447b-8592-1c6c91aa1b9a Ixekizumab/methotrexate/secukinumab - AdisInsight In a study of 4 patients with spongiotic psoriasiform dermatitis (SD/PSO), 3 men aged 53-72 years were described, who developed abnormal liver function, ixekizumab methotrexate secukinumab adisinsight https://adisinsight.springer.com/drugsafety/803405847?error=cookies_not_supported&code=e963824c-f762-4576-94d9-6b980750c78c Pembrolizumab/secukinumab - AdisInsight An 80-year-old man developed psoriasiform skin reaction and thrombocytopenia during treatment with pembrolizumab and secukinumab, respectively.The man had a pembrolizumab secukinumab adisinsight https://adisinsight.springer.com/drugsafety/803926520?error=cookies_not_supported&code=653b0357-1725-44d9-9cd1-3313ddf7ccdf Secukinumab - AdisInsight A 33-year-old man with ankylosing spondylitis developed a pustular eruption during treatment with secukinumab. The man had been receiving secukinumab 150 mg secukinumab adisinsight